Company: PBH
Filing Date: 2025-02-06
Form Type: 10-Q
Source: 0001295947-25-000009
Chunk: 16

Company: Prestige Consumer Healthcare Inc.
Filing Date: 2025-02-06
Form: 10-Q
Item: Item 2
Chunk 16
---
 Cough & Cold18,304 2.2 19,129 2.3 (825)(4.3)Women's Health14,560 1.7 17,218 2.0 (2,658)(15.4)Gastrointestinal58,347 6.9 49,678 5.9 8,669 17.5 Eye & Ear Care18,240 2.2 17,715 2.1 525 3.0 Dermatologicals6,076 0.7 3,972 0.5 2,104 53.0 Oral Care9,696 1.2 9,591 1.1 105 1.1 Other OTC935 0.1 118 — 817 692.4 Total International OTC Healthcare130,183 15.5 121,235 14.3 8,948 7.4 Total Consolidated$841,244 100.0 $848,366 100.0 $(7,122)(0.8)

Total revenues for the nine months ended December 31, 2024 were $841.2 million, a decrease of $7.1 million, or 0.8%, versus the nine months ended December 31, 2023.    

North American OTC Healthcare Segment

Revenues for the North American OTC Healthcare segment decreased $16.1 million, or 2.2%, during the nine months ended December 31, 2024 versus the nine months ended December 31, 2023.  The $16.1 million decrease was primarily attributable to a decrease in sales in the Cough & Cold, Women's Health, and Oral Care categories, partly offset by an increase in sales in the Gastrointestinal category.  

International OTC Healthcare Segment

Revenues for the International OTC Healthcare segment increased $8.9 million, or 7.4%, during the nine months ended December 31, 2024 versus the nine months ended December 31, 2023. The $8.9 million increase was mainly attributable to an increase in sales in the Gastrointestinal and Dermatologicals categories, partly offset by a decrease in sales in the Women's Health category.

-27-

Gross Profit

The following table presents our gross profit and gross profit as a percentage of total segment revenues,